A French Real-life Study: EvaluatioN of durvALumab utilization and effectiveness for first line extensive stage small cell lung cancer.

Trial Identifier: D419QR00014
Kappa Santé
Start Date:November 2022
Primary Completion Date: April 2027
Study Completion Date: April 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

France ANGERS, France
France Argenteuil, France
France Avignon, France
France Avignon, France
France Bayonne, France
France Bordeaux Cedex, France
France Clermont-Ferrand, France
France Creteil, France
France Epagny Metz-Tessy, France
France Evreux, France
France Gleize, France
France La Roche sur Yon, France
France La Rochelle, France
France Le Chesnay-Rocquencourt, France
France Marseille, France
France Nimes, France
France OSNY, France
France Pau, France
France RENNES, France
France Rouen, France
France Saint Gregoire, France
France Saint-Etienne, France
France Toulon, France
France Toulouse, France
France TOULOUSE, France
France Valenciennes, France
France VANNES, France